Higher dose glatiramer acetate more effective in MS

    loading  Checking for direct PDF access through Ovid

Abstract

A higher dose of glatiramer acetate [Copaxone] demonstrated increased efficacy in patients with relapsing-remitting multiple sclerosis (MS) in a study presented as a late breaking science platform at the 58th Annual Meeting of the American Academy of Neurology (AAN) [San Diego, California, US; April 2006]. The randomised, double-blind, multicentre phase II study showed that a 40mg dose of glatiramer acetate was associated with a 38% greater reduction in the mean cumulative number of gadolinium (Gd)-enhancing lesions, compared with the currently approved 20mg dose. Compared with the annual relapse rate at baseline, patients receiving the 40mg dose of glatiramer acetate experienced a reduction of 77%, compared with a 62% reduction in patients receiving the 20mg dose.

Related Topics

    loading  Loading Related Articles